drugset
Drugs / Ad26.Mos.HIV
last change Apr 2022 re-read 9 days ago

Ad26.Mos.HIV

Vaccine

Developed for
HIV infectious disease
Investigated by
Janssen Vaccines & Prevention B.V. · Beth Israel Deaconess Medical Center · International AIDS Vaccine Initiative · National Institute of Allergy and Infectious Diseases (NIAID) · US Military HIV Research Program

Trials 4

today NCT02919306 · Ph 1/2 NCT02788045 · Ph 1/2 NCT02685020 · Ph 1 NCT02315703 · Ph 1/2
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT02685020 Mar 2016 → Jan 2018 — Janssen Vaccines & Prevention B.V. Completed No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT02919306 Sep 2016 → Sep 2018 HIV infectious disease Janssen Vaccines & Prevention B.V. Completed No outcome recorded
Phase 1/2 NCT02788045 Jul 2016 → Apr 2022 — Janssen Vaccines & Prevention B.V. Completed No outcome recorded
Phase 1/2 NCT02315703 Dec 2014 → Aug 2017 — Janssen Vaccines & Prevention B.V. Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Ad26.Mos.HIV ClinicalTrials.gov intervention name — accepted as the source's own label NCT02919306 ↗
3

NCT02685020 ↗

NCT02315703 ↗

NCT02788045 ↗
Modality Vaccine “Recombinant replication-deficient Ad26 vectored vaccine” NCT02315703 ↗
Route Intramuscular “administered intramuscularly” NCT02315703 ↗